rAAt (inhaled) Arriva/Hyland Immuno.
Article Details
- CitationCopy to clipboard
Brown WM
rAAt (inhaled) Arriva/Hyland Immuno.
Curr Opin Mol Ther. 2006 Feb;8(1):76-82.
- PubMed ID
- 16506529 [ View in PubMed]
- Abstract
Arriva Pharmaceuticals Inc and Hyland Immuno are developing a nebulized formulation of the recombinant alpha1-antitrypsin (rAAT) for the potential treatment of respiratory disorders, including emphysema, asthma and chronic obstructive pulmonary disease. The therapy, as a nebulized formulation, is currently undergoing phase II clinical trials.
DrugBank Data that Cites this Article
- Drugs